Sunho Biologics (HKSE:02898) Inventories, Other : HK$1.10 Mil (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Sunho Biologics Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Sunho Biologics's other inventories for the quarter that ended in Jun. 2024 was HK$1.10 Mil.

Sunho Biologics's quarterly other inventories stayed the same from Jun. 2023 (HK$0.00 Mil) to Dec. 2023 (HK$0.00 Mil) but then increased from Dec. 2023 (HK$0.00 Mil) to Jun. 2024 (HK$1.10 Mil).

Sunho Biologics Inventories, Other Historical Data

The historical data trend for Sunho Biologics's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunho Biologics Inventories, Other Chart

Sunho Biologics Annual Data

Trend

Dec22

Dec23

Dec24

Inventories, Other

1.04

Sunho Biologics Semi-Annual Data
	Dec22	Jun23	Dec23	Jun24	Dec24
Inventories, Other	-	-	-	1.10	1.04

Sunho Biologics Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.

Sunho Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunho Biologics Inc (HKSE:02898) » Definitions » Inventories, Other

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 198 Peninsula Middle Road, Dipu Street, Room 302, Building 3, Anji County, Zhejiang Province, Huzhou, CHN

Website

http://www.sunho-bio.com.cn

Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.

Executives

Sunho Fortune Investments Limited	2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited	2301 Trustee
Zhang Feng	2201 Interest of corporation controlled by you
Sunho Wisdom Investments Limited	2101 Beneficial owner

Sunho Biologics Headlines

No Headlines